Migraine | Disease Landscape & Forecast | G7 | 2023
Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of calcitonin gene-related peptide (CGRP)-targeted, migraine-specific treatment alternatives to standard-of-care (SOC) therapies (e.g., anti-CGRP MAbs for migraine prevention, oral CGRP receptor antagonists for both the treatment of acute migraine attacks and migraine prevention) and the expected launches of several innovative reformulations of SOC therapies in the near term in the United States, brand choice has rapidly expanded in this heavily generic market. Understanding the intersecting forces of unmet need, cost/coverage, and the headwinds posed by low-cost, early-line SOC treatments will be key to the success of current and future players in the migraine market.
Questions Answered:
- What events will shape the future of the acute/preventive and episodic/chronic market segments?
- How are the anti-CGRP monoclonal antibodies (e.g., Aimovig, Emgality) and oral gepants (i.e., Nurtec ODT / Vydura, Qulipta) being integrated into the generic-dominant migraine prophylaxis market? Which brands will be the most competitive and why?
- What is the dynamic between Ubrelvy and Nurtec ODT in the U.S. market? How are oral gepants being adopted into the triptan-dominant acute segment?
- How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 33 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.
Epidemiology: Total, diagnosed, and drug-treated prevalent cases of episodic and chronic migraine, segmented by acute and prophylactic treatment.
Emerging therapies: Phase 2: 7 drugs; Phase 3 / preregistration: 3 drugs.
Market forecast features: Patient-based market forecast extending through 2032, segmented by brands and generics.
Product Description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement:
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
